1877:HKEXNANO Co., Ltd. Analysis

Data as of 2026-08-02 - not real-time

HK$18.26

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Shanghai Junshi Biosciences (1877.HK) is trading at HK$18.26, well below its 20‑day SMA (HK$18.96) and 50‑day SMA (HK$18.49), with a bearish MACD histogram and decreasing volume, indicating short‑term pressure. However, the stock enjoys a strong upside potential of roughly 58% (target median HK$31.80) and sits in the “Extreme Greed” zone of the fear‑greed index, suggesting bullish sentiment.
Fundamentally, the company posted 45% revenue growth and a 78% gross margin, but remains loss‑making with negative operating cash flow, a high debt‑to‑equity of 98%, and a negative EPS. Recent material news – NDA acceptance for toripalimab (JS001sc), successful Phase 3 endpoints, and strategic collaborations with Antengene and Fosun Wanbang – provide tangible catalysts that could translate the pipeline into revenue and improve the balance sheet over the coming years.

Market Outlook

Short Term

< 1 year

Neutral

Model confidence: 6/10

Key Factors

Bearish technical indicators (price below SMA20/50, negative MACD)
Recent NDA acceptance and Phase 3 data could trigger a short‑term rally
Support level at HK$17.52 provides downside cushion

Medium Term

1–3 years

Positive

Model confidence: 8/10

Key Factors

Strong pipeline with multiple Phase 3 trials nearing commercialization
Strategic collaborations expanding market reach and co‑development potential
Analyst consensus of strong‑buy and target median price near HK$32

Long Term

> 3 years

Positive

Model confidence: 8/10

Key Factors

High revenue growth and robust gross margins indicate scalable business model
Potential to convert pipeline assets into blockbuster products, improving profitability
Long‑term upside supported by sizable market cap relative to cash reserves despite current leverage